INTRODUCTION {#s1}
============

Numerous reports have described the increasing problem of nosocomial invasive fungal infections (IFI) in immunocompromised patients ([@B1], [@B2]). This is due to the increased number of at-risk patients in parallel with progress in intensive care and/or hematology, leading to deeper or longer immunosuppression ([@B3]). In parallel, the spectrum of isolated fungi has shifted from well-known opportunistic pathogens with characterized virulence factors ([@B4], [@B5]) to other species rarely reported to be a cause of human infection ([@B6][@B7][@B8]). Disruptions in the microbial balance induced by antibacterial antibiotics favor fungal fitness ([@B9]). Antifungal therapy is generally prescribed in patients with persistent fever despite 3 days of antibiotic treatment ([@B10]). Diagnostic strategies involve conventional methods of isolation and identification of fungi from blood or sterile sites, imaging, and a panel of biological tests whose nature depends on the fungal agent suspected ([@B11], [@B12]). The few biological tests currently considered by physicians to be of diagnostic help do not involve changes in the host response related to fungal infections (e.g., antifungal antibodies \[[@B13]\] or cytokine profiling \[[@B14]\]) but consist of the detection of circulating fungal molecules, either glycans or DNA, in the patients\' sera using tests developed with the advent of hybridoma technology ([@B15], [@B16]), discoveries in biochemical cascades ([@B17]), or PCR ([@B18]). Due to the poor sensitivity of conventional mycological methods ([@B12], [@B19]), infectious disease societies have produced different levels of recommendations for immunological tests for the diagnosis of invasive candidiasis (IC) and invasive aspergillosis (IA) ([@B20], [@B21]). These tests, which are considered specific but which sometimes lack sensitivity, were later complemented by recommendations for the more sensitive Fungitell test, which detects both IC and IA ([@B22]). Despite years of extensive research into the detection of fungal DNA, a consensus has been reached only for IA, while standardization is still in progress for IC and mucormycosis (MM) ([@B23]). For MM, a standardized PCR method would be of primary interest since, in contrast to IC, glycan detection tests are not available ([@B24]). Recently, the T2MR technology, combining DNA amplification and detection by magnetic resonance, has provided significant progress in terms of reducing the delay in the time to diagnosis in comparison with the time to diagnosis by blood cultures for IC ([@B25]). More recently, matrix-assisted laser desorption ionization--time of flight (MALDI-TOF) mass spectrometry (MS) has become essential in clinical mycology laboratories, providing a more rapid and accurate means of identification of fungal species isolated from patients ([@B26]).

We developed an approach based on the ability of MS to detect fungal molecules in patients' sera ([@B27]). Subsequent work showed that this method, which allows the detection and relative quantification of a panfungal serum disaccharide (DS), gave results that were comparable to those of methods recommended for the diagnosis of IFI ([@B28]). Here, we describe the results of a European collaborative study carried out in a blind manner to validate the use of MS for DS (MS-DS) for the diagnosis of IFI.

(This study was presented in part at the Russian Scientific Conference on Medical Microbiology and Clinical Mycology, Saint Petersburg, Russia, 14 to 16 June 2016; at the 13th Annual Fungal Update meeting, St Bartholomew\'s Hospital, London, United Kingdom, 2 to 3 March 2018; and as an e-poster at the 20th Congress of the International Society for Human and Animal Mycology, Amsterdam, Netherlands, 30 June to 4 July 2018 \[[@B29]\].)

MATERIALS AND METHODS {#s2}
=====================

Study design and participants. {#s2.1}
------------------------------

Different centers provided sera from patients with IFI classified as proven or probable according to the European Organization for the Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG) criteria ([@B30]). Patients with IC were selected at the University Hospital of Genoa and Catholic University of Sacred Heart, Rome, Italy. Controls for IC patients consisted of febrile patients who were admitted to the Emergency Department of the University Hospital of Lausanne, Lausanne, Switzerland, and in whom bacteremia was subsequently documented. Two cases of nocardiosis from Lille University Hospital were also included among the controls. Patients with IA were selected at the University Hospital of Strasbourg, Strasbourg, France. Controls consisted of neutropenic patients hospitalized at the University Hospital of Genoa. Patients with MM were selected at Saint Louis University Hospital, Paris, France, and Lille University Hospital, Lille, France.

Altogether 95 patients and 189 serum and plasma samples were selected. They were distributed as follows: 17 patients with IC (27 serum samples), 19 patients with IA (53 serum samples), 16 patients with MM (36 serum samples), 10 control neutropenic patients (20 serum samples), 20 patients (21 plasma samples) with bacterial infections, and 2 patients with *Actinomycete* infections (2 serum samples).

MS-DS detection. {#s2.2}
----------------

Serum and plasma samples were frozen and sent on dry ice to the Laboratory of Clinical Mycology, Lille University Hospital, for processing as described previously ([@B27]). After a preanalytical step for the extraction and purification of oligosaccharides, spectra were recorded and analyzed using a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems/MDS Sciex) at a fixed laser intensity within a 300- to 800-*m/z* range (UMR CNRS 8576, University of Lille).

Detection of circulating poly- and oligosaccharides and DNA in serum or plasma. {#s2.3}
-------------------------------------------------------------------------------

For the diagnosis of IC and IA, detection of mannan (Man) or galactomannan (GM) and (1,3)-β-[d]{.smallcaps}-glucan (BDG) was performed in the participating centers during routine patient screening or in the Lille Clinical Mycology Laboratory if they had not been tested previously.

BDG was measured using a Fungitell kit (Associates of Cape Cod Inc., Falmouth, MA, USA) following the manufacturer's instructions. The recommended cutoff of 80 pg/ml was used to determine clinical relevance.

Measurement of serum Man and GM was performed using a Platelia Candida Ag Plus test and Platelia Aspergillus Ag test (Bio-Rad, Marnes la Coquette, France), respectively, according to the manufacturer\'s instructions. The recommended cutoffs of a concentration of 62.5 pg/ml and an index of ≥0.5, respectively, were used.

For the diagnosis of MM, quantitative real-time PCR (qPCR) was performed as described previously ([@B24], [@B31]).

Ethics statement. {#s2.4}
-----------------

No additional sampling was necessary in any center due to the retrospective nature of the study. In Lille, agreement for the establishment of a biological collection of IFI samples was obtained from the French Ministry of Education and Research under reference number DC2008-642. Institutional review board approval was granted by the Comité de Protection des Personnes Nord-Ouest IV, the ethical committee of the university hospital of Lille.

Statistical analysis. {#s2.5}
---------------------

GraphPad Prism (version 6) software was used to compare the distribution of biomarkers in the different groups with the Mann-Whitney two-tailed test and to generate receiver operating characteristic (ROC) curves, derive cutoffs, and construct graphs. A *P* value of \<0.05 was considered statistically significant.

RESULTS {#s3}
=======

Invasive candidiasis. {#s3.1}
---------------------

**(i) Study population.** The origin of the IC patients, the delay to serum sampling in relation to the time of the first positive blood culture, and the *Candida* species isolated are shown in [Table 1](#T1){ref-type="table"}. The *Candida* species were representative of the usual epidemiology encountered in southern Europe, with a higher prevalence of Candida parapsilosis complex isolates. The control patients with bacteremia are listed in [Table 2](#T2){ref-type="table"}. These included the usual panel of patients with community-acquired bacterial infections and two cases of *Nocardia* infection.

###### 

Origin of sera from patients with IC, delay between serum sampling and time of first positive blood culture, and *Candida* species isolated[^*a*^](#T1F1){ref-type="table-fn"}

  Patient no. (site)   Species isolated   Delay vs BC (days)   Man concn (pg/ml)   BDG concn (pg/ml)   MS-DS index
  -------------------- ------------------ -------------------- ------------------- ------------------- -------------
  I1 (G)               Candida albicans   2                    **\>500**           **688**             **2,000**
                       C. albicans        5                    **\>500**           **1,528**           **550**
                       C. albicans        7                    **\>500**           **861**             **625**
  I2 (G)               C. albicans        2                    **81**              **943**             79
                       C. albicans        5                    **192**             **405**             133
                       C. albicans        7                    **79**              **286**             200
  I3 (G)               C. albicans        2                    **69**              **155**             **400**
                       C. albicans        7                    30                  **108**             **526**
                       C. albicans        13                   12                  50                  300
  I4 (G)               C. albicans        0                    **\>500**           **5,000**           **1,000**
                       C. albicans        5                    **\>500**           **5,000**           **333**
                       C. albicans        7                    **\>500**           **5,000**           285
  I5 (G)               C. albicans        1                    **441**             **407**             133
                       C. albicans        6                    22                  **222**             110
                       C. albicans        10                   38                  **336**             300
  I6 (G)               C. albicans        −5                   **108**             **403**             70
                       C. albicans        0                    **150**             **283**             85
                       C. albicans        4                    **232**             **2,528**           500
  I7 (G)               C. albicans        2                    **\>500**           **850**             350
                       C. albicans        10                   **\>500**           **367**             667
  I8 (G)               C. albicans        1                    41                  **158**             238
                       C. albicans        7                    39                  58                  151
  I9 (R)               C. albicans        1                    4                   **\>500**           **1,000**
  I10 (R)              C. albicans        2                    0                   **\>500**           **385**
  I11 (R)              C. albicans        1                    3                   **\>500**           175
                       C. albicans        0                    3                   **\>500**           **435**
  I12 (R)              C. albicans        1                    **\>500**           **\>500**           159
  I13 (R)              C. albicans        1                    0                   **\>500**           122
  I14 (R)              C. glabrata        0                    **64**              **\>500**           78
  I15 (G)              C. tropicalis      3                    **\>500**           **159**             110
                       C. tropicalis      7                    18                  **189**             **357**
                       C. tropicalis      14                   31                  42                  **345**
  I16 (R)              C. tropicalis      3                    \>500               \>500               **714**
  I17 (G)              C. parapsilosis    2                    5                   61                  53
                       C. parapsilosis    5                    0                   **245**             172
                       C. parapsilosis    6                    **82**              7                   238
  I18 (G)              C. parapsilosis    1                    16                  **125**             122
                       C. parapsilosis    4                    14                  **159**             **400**
                       C. parapsilosis    14                   34                  70                  **667**
  I19 (G)              C. parapsilosis    0                    21                  26                  159
                       C. parapsilosis    4                    18                  77                  65
  I20 (G)              C. parapsilosis    −1                   **110**             39                  **833**
                       C. parapsilosis    3                    6                   20                  **450**
  I21 (R)              C. parapsilosis    1                    2                   **\>500**           **1,000**
  I22 (R)              C. parapsilosis    1                    NA                  **\>500**           109
                       C. parapsilosis    1                    NA                  **\>500**           106
  I23 (R)              C. parapsilosis    7                    **256**             **\>500**           333
  I24 (R)              C. parapsilosis    0                    0                   **\>500**           96
  I25 (R)              C. orthopsilosis   1                    **\>500**           **\>500**           769
                       C. orthopsilosis   1                    **\>500**           **\>500**           588
                       C. orthopsilosis   1                    **\>500**           **\>500**           **1,000**
                       C. orthopsilosis   1                    **\>500**           **\>500**           **625**
  I26 (G)              C. krusei          3                    12                  **327**             **357**
                       C. krusei          7                    10                  **385**             **344**
                       C. krusei          10                   8                   **191**             **400**
  I27 (G)              C. krusei          2                    12                  7                   300
                       C. krusei          4                    16                  14                  167

BC, time of first positive blood culture; BDG, (1,3)-β-[d]{.smallcaps}-glucan; G, Genoa, Italy; Man, mannan; MS-DS, mass spectrometry method for detection of a serum disaccharide; NA, not available; R, Rome, Italy. Bold characters correspond to positive values.

###### 

Origin of the control sera used in the MS-DS test for invasive candidiasis[^*a*^](#T2F1){ref-type="table-fn"}

  Patient no. (site)   Reason(s) for hospitalization         Risk factor(s) for fungal infection                         Species isolated                                                      Delay vs BC (days)   Man concn (pg/ml)   BDG concn (pg/ml)   MS-DS index
  -------------------- ------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------- -------------------- ------------------- ------------------- -------------
  S1                   Septic shock, infected kidney stone   Corticosteroids, panhypopituitarism (substitution)          Escherichia coli                                                      −1                   2                   **97**              230
  S2                   Septic shock, urinary infection       MGUS, CRF, corticosteroids (unconfirmed Horton's disease)   E. coli                                                               0                    3                   **83**              **286**
  S3                   Cholangitis                           Corticosteroids, polymyalgia rheumatica                     E. coli                                                               0                    4                   7                   70
  S4                   Urosepsis                             IDDM, PPI                                                   E. coli                                                               0                    1                   7                   65
  S5                   Urosepsis                             CRF, chronic ulcers, gout                                   E. coli                                                               0                    9                   **169**             **400**
  S6                   Cholecystitis                         PPI                                                         E. coli                                                               0                    3                   29                  122
  S7                   Urosepsis                             CRF, corticosteroids, polymyalgia rheumatica, PPI           E. coli                                                               0                    0                   7                   **667**
  S8                   Urosepsis                             Indwelling urinary catheter                                 E. coli                                                               0                    0                   **122**             43
  S9                   Skin infection                        CRF                                                         Streptococcus agalactiae                                              0                    0                   7                   120
  S10                  Skin infection                        None                                                        Streptococcus dysgalactiae                                            0                    2                   7                   154
  S11                  Skin infection                        None                                                        S. dysgalactiae                                                       0                    1                   22                  76
  S12                  Pneumococcal pneumonia                NIDDM                                                       Streptococcus pneumoniae                                              0                    3                   7                   55
  S13                  Pneumonia                             None                                                        Streptococcus pyogenes                                                0                    4                   7                   **500**
  S14                  Plantar abscess                       IDDM, metabolic syndrome                                    S. pyogenes                                                           0                    0                   7                   115
  S15                  Wound infection                       IDDM, diffuse vascular disease, PPI                         Staphylococcus aureus                                                 0                    4                   **280**             238
  S16                  Endocarditis/spondylodiscitis         PPI                                                         S. aureus                                                             4                    2                   7                   53
  S17                  Pyelonephritis                        IDDM                                                        Klebsiella pneumoniae                                                 1                    7                   7                   54
  S18                  Urosepsis                             Indwelling urinary catheter                                 Proteus mirabilis                                                     2                    3                   77                  65
  S19                  Stroke, dental abscess                Diffuse cerebrovascular disease, PPI                        Parvimonas micra                                                      0                    1                   7                   106
  S20                  Skin infection                        IDDM, diffuse vascular disease                              *Corynebacterium* spp.                                                0                    4                   7                   104
  S21                  Cholangitis                           None                                                        Enterococcus faecalis, Enterobacter cloacae, Pseudomonas aeruginosa   0                    2                   7                   115
  L1                   Pneumonia                             Renal graft and leukemia                                    Nocardia nova                                                         −2                   0                   35                  72
  L2                   Skin infection and adenitis           Renal graft                                                 N. nova                                                               −5                   0                   **2,336**           **131**

BC, time of first positive blood culture; BDG, (1,3)-β-[d]{.smallcaps}-glucan; CRF, chronic renal failure; IDDM, insulin-dependent diabetes mellitus; L, Lille, France; Man, mannan; MGUS, monoclonal gammopathy of undetermined significance; MS-DS, mass spectrometry method for detection of a serum disaccharide; NNIDDM, non-insulin-dependent diabetes mellitus; PPI, proton pump inhibitor; S, Switzerland. Bold characters correspond to positive values.

**(ii) MS-DS diagnosis of IC in comparison to BDG and Man detection.** The distribution of BDG and Man concentrations and MS-DS index values is shown in [Fig. 1](#F1){ref-type="fig"}. All tests significantly discriminated IC patients from bacteremic controls (*P* \< 0.0001).

![Distribution of MS-DS indexes (A), Man concentrations (B), and BDG concentrations (C) in patients with invasive candidiasis (IC) versus the controls. The results for each biomarker for the patient and control groups were compared using the Mann-Whitney test (significant at *P* ≤ 0.05). The dotted lines represent the cutoff values for each biomarker.](JCM.01867-18-f0001){#F1}

Among the 27 IC patients, 9 were positive by all three tests, 12 were positive by two tests (6 by BDG detection and MS-DS; 5 by BDG and Man detection; 1 by Man detection and MS-DS), and 4 were positive by BDG detection alone. Only two patients (patients I19 and I27) infected by C. parapsilosis and C. krusei were negative by all tests. When considering control patients with bacteremia, three were positive by MS-DS, whereas six were positive for BDG, including the patient with *Nocardia* infection who displayed very high glucan levels. Only one control (patient S5) was positive for two biomarkers (BDG and DS).

[Figure 2](#F2){ref-type="fig"} shows the ROC curves and corresponding sensitivities and specificities for the MS-DS, BDG, and Man detection tests. When considering the results for serum samples ([Fig. 2A](#F2){ref-type="fig"} and [B](#F2){ref-type="fig"}), application of the cutoff value of 325 for MS-DS showed a sensitivity of 51% and a specificity of 87%, which were intermediate values compared to those obtained by the BDG and Man tests. Analysis of the MS-DS index values for IC diagnosis was then performed for patients ([Fig. 2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}), and the sensitivity reached 67% without altering the high specificity estimated for serum. Comparison of ROC curves established for the MS-DS and the BDG and Man tests revealed that the diagnostic value of MS-DS was similar to that of the BDG test and positively complemented the high specificity of Man monitoring (revealed by the asymptotic curve). A lack of concordance between MS-DS and the BDG and Man tests was observed for serial serum samples from a given patient. This appeared to be more moderate when considering the global biomarker patterns per patient, since most patients (22/26) aggregated into two groups: those that displayed three positive test and those that displayed two positive tests. [Figure 3A](#F3){ref-type="fig"} shows an example of biomarker kinetics during the time course of IC in one patient. Tests for BDG and Man were positive on day 1 and decreased on day 7, whereas MS-DS became positive at the end of monitoring. Due to the retrospective nature of the study, few serum samples were available per patient, but analysis of the whole IC patient population confirmed the transient nature of Man detection, in contrast to a slower decrease in glucanemia.

![(A, C) ROC curves for serum (A) and patients (C) for invasive candidiasis. Gray, dashed, and black lines, results for BDG detection, Man detection, and MS-DS, respectively. (B, D) Sensitivity/specificity values according to preestablished cutoff values for each biomarker for analysis of serum (B) and patients (D). AUC, area under the concentration-time curve.](JCM.01867-18-f0002){#F2}

![Examples of kinetics of serum biomarkers in patients with invasive candidiasis (IC) (A), invasive aspergillosis (IA) (B), and mucormycosis (MM) (C). Day 0 indicates the date of a positive fungal blood culture (BC) for IC or the first available serum sample for IA and the date of mycological evidence for MM. (A, B) Black circles and black solid line, MS-DS; black triangles and dashed line, Man or GM detection; black squares and gray line, BDG detection. Biomarker levels are indicated on the *y* axis with reference to BDG values (pg/ml), MS-DS index, and GM (index × 1,000). (C) Empty and full circles, negative and positive Mucorales qPCR results, respectively, for MM patients. Horizontal dotted lines indicate the cutoff values for BDG (80 pg/ml), Man (62.5 pg/ml), GM (index value, 0.5 · 1,000), and MS-DS (index value, 325). d, day.](JCM.01867-18-f0003){#F3}

Invasive aspergillosis. {#s3.2}
-----------------------

**(i) Study population.** The characteristics of the IA patients, the level of certainty of a diagnosis of IA according to EORTC criteria, and the *Aspergillus* species isolated are shown in [Table 3](#T3){ref-type="table"}. Except for one patient with invasive sinusitis, all patients presented with invasive pulmonary aspergillosis. "Day 0" indicates the date of the first serum available in the collection relative to the episodes of IA defined according to clinical and radiological arguments.

###### 

Origins of sera from patients with invasive aspergillosis, *Aspergillus* species isolated, and level of evidence of *Aspergillus* infection[^*a*^](#T3F1){ref-type="table-fn"}

  Patient no.   Age (yr)   Sex   Underlying condition(s)                    Species isolated        EORTC classification   Treatment                Outcome                              GM in BAL fluid   Delay between serum sample collections (days)   BDG concn (pg/ml)   GM index in serum   MS-DS index
  ------------- ---------- ----- ------------------------------------------ ----------------------- ---------------------- ------------------------ ------------------------------------ ----------------- ----------------------------------------------- ------------------- ------------------- -------------
  A1            44         M     Heart transplant                           Aspergillus fumigatus   Proven IPA             VCZ                      Complete remission, alive at wk 12   NA                0                                               **4,279**           **\>6**             **350**
                                                                                                                                                                                                           7                                               **5,000**           **4.06**            **333**
                                                                                                                                                                                                           17                                              **4,362**           **2.63**            **555**
                                                                                                                                                                                                           24                                              **4,045**           **2.12**            **333**
  A2            56         M     CLL with Richter transformation            NA                      Probable IPA           VCZ                      Progression, death on day 28         Pos               0                                               **134**             **1.09**            123
                                                                                                                                                                                                           11                                              42                  0.17                **400**
                                                                                                                                                                                                           16                                              **98**              0.16                **714**
  A3            90         M     AML                                        A. fumigatus            Probable IPA           VCZ                      Progression, death on day 44         NA                0                                               7                   0.09                113
  A4            63         M     COPD, corticosteroids, diabetes mellitus   A. fumigatus            Probable IPA           VCZ                      Complete remission, alive at wk 12   NA                0                                               **1,643**           **1.59**            58
  A5            35         M     Lymphoma, MAS                              NA                      Probable IPA           VCZ                      Progression, death on day 66         NA                0                                               60                  **0.97**            90
                                                                                                                                                                                                           3                                               79                  **0.55**            76
  A6            56         F     Liver transplant                           A. fumigatus            Probable IPA           VCZ                      Complete remission, alive at wk 12   NA                0                                               **489**             **2.30**            **3,333**
                                                                                                                                                                                                           8                                               **235**             **0.87**            **1,250**
                                                                                                                                                                                                           15                                              **340**             **0.57**            **2,000**
  A7            59         M     Liver transplant                           Aspergillus nidulans    Probable IPA           VCZ and then VCZ + CAS   Progression, death on day 84         Pos               0                                               40                  **1.02**            **526**
                                                                                                                                                                                                           10                                              78                  **0.54**            **400**
                                                                                                                                                                                                           21                                              64                  0.34                **526**
  A8            56         M     ALL                                        NA                      Probable IPA           VCZ                      Progression, alive at wk 12          Pos               0                                               7                   0.06                105
                                                                                                                                                                                                           10                                              7                   0.05                135
                                                                                                                                                                                                           19                                              35                  0.05                72
  A9            32         M     Testicular cancer                          NA                      Probable IPA           VCZ and then L-AMB       Progression, death on day 71         Pos               0                                               73                  **1.37**            **1,250**
                                                                                                                                                                                                           4                                               **102**             **0.67**            **1,667**
                                                                                                                                                                                                           10                                              66                  0.35                **3,333**
  A10           53         F     AML, Allo-HSCT                             A. fumigatus            Proven IA sinusitis    L-AMB                    Partial response, death on day 61    NA                0                                               7                   **0.55**            87
                                                                                                                                                                                                           3                                               36                  **0.98**            **625**
                                                                                                                                                                                                           9                                               7                   0.22                **1,000**
  A11           54         M     Heart and liver transplant                 A. fumigatus            Probable IPA           VCZ and then L-AMB       Progression, death on day 82         Pos               0                                               **949**             0.44                **714**
                                                                                                                                                                                                           14                                              **1,999**           0.51                **333**
                                                                                                                                                                                                           21                                              **1,776**           0.31                **833**
  A12           26         M     Lymphoma, HTLV-1, Allo-HSCT                NA                      Probable IPA           VCZ                      Stable, alive at wk 12               NA                0                                               **208**             3.32                **1,429**
                                                                                                                                                                                                           3                                               **454**             **0.56**            **5,000**
                                                                                                                                                                                                           14                                              **312**             0.31                **1,429**
  A13           62         M     CMML, COPD                                 A. fumigatus            Probable IPA           VCZ and then VCZ + CAS   Partial response, alive at wk 12     Pos               0                                               **238**             0.13                127
                                                                                                                                                                                                           11                                              **195**             0.07                78
                                                                                                                                                                                                           15                                              **217**             0.06                83
  A14           47         M     Posthepatitis liver fibrosis               A. fumigatus            Probable IPA           L-AMB                    Progression, death on day 27         Pos               0                                               31                  0.20                **1,667**
                                                                                                                                                                                                           4                                               48                  0.13                **1,429**
                                                                                                                                                                                                           7                                               30                  0.16                **1,429**
  A15           71         M     Multiple myeloma                           NA                      Probable IPA           VCZ                      Progression, death on day 54         Pos               0                                               7                   0.08                **333**
                                                                                                                                                                                                           3                                               7                   0.08                **400**
                                                                                                                                                                                                           9                                               7                   0.07                300
  A16           60         M     AML                                        NA                      Probable IPA           VCZ                      Progression, death on day 21         Pos               0                                               27                  **2.39**            149
                                                                                                                                                                                                           7                                               7                   **1.89**            52
  A17           51         M     Lymphoma                                   NA                      Probable IPA           VCZ and then L-AMB       Complete response, alive at wk 12    NA                0                                               12                  **0.73**            61
                                                                                                                                                                                                           4                                               7                   0.11                109
                                                                                                                                                                                                           6                                               20                  0.07                238
  A18           73         M     CLL                                        NA                      Probable IPA           VCZ                      Progression, death on day 31         NA                0                                               73                  **0.82**            109
                                                                                                                                                                                                           11                                              **292**             **\>6**             **588**
                                                                                                                                                                                                           24                                              **111**             **3.08**            **625**
  A19           39         F     Lymphoma                                   NA                      Probable IPA           VCZ and then L-AMB       Progression, death on day 61         NA                0                                               **3,030**           **\>6**             **714**
                                                                                                                                                                                                           8                                               **517**             **3.34**            **2,000**
                                                                                                                                                                                                           15                                              **479**             **1.22**            **3,333**

ALL, acute lymphoblastic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; BDG, (1,3)-β-[d]{.smallcaps}-glucan; CAS, caspofungin; CLL, chronic lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia; COPD, chronic obstructive pulmonary disease; EORTC, European Organization for Research and Treatment of Cancer; F, female; GM, galactomannan; HTLV-1, human T cell leukemia virus type 1; IPA, invasive pulmonary aspergillosis; L-AMB, liposomal amphotericin B; M, male; MAS, macrophage activation syndrome; MS-DS, mass spectrometry method for detection of a serum disaccharide; NA, not available; Pos, positive; VCZ, voriconazole. Bold characters correspond to positive values.

The characteristics of the controls, consisting of neutropenic patients, are summarized in [Table 4](#T4){ref-type="table"}. Retrospective analysis of the clinical evolution of IA revealed that control patients 3, 6, and 7 developed probable IA 1, 2, and 6 months after serum sampling, respectively.

###### 

Origin of control sera used in MS-DS test for invasive aspergillosis[^*a*^](#T4F1){ref-type="table-fn"}

  Patient no.   Age (yr)   Sex   Underlying condition(s)                       Antifungal prophylaxis   Delay between serum sample collections (days)   BDG concn (pg/ml)   GM index in serum   MS-DS index
  ------------- ---------- ----- --------------------------------------------- ------------------------ ----------------------------------------------- ------------------- ------------------- -------------
  1             50         M     Neutropenia, myelofibrosis                    Fluconazole              0                                               7                   0.07                68
                                                                                                        3                                               7                   0.08                86
  2             40         M     Neutropenia, Hodgkin's disease                Fluconazole              0                                               7                   0.09                147
                                                                                                        4                                               7                   0.06                143
  3             48         F     Neutropenia, Allo-HSCT (ALL)                  No                       0                                               7                   0.18                200
                                                                                                        5                                               7                   0.21                81
  4             44         F     Neutropenia/GVHD, Allo-HSCT (myelofibrosis)   Posaconazole             0                                               7                   0.04                161
                                                                                                        1                                               7                   0.04                120
  5             21         F     Neutropenia, Allo-HSCT (AML)                  Posaconazole             0                                               7                   0.05                66
                                                                                                        7                                               7                   0.05                39
  6             49         M     Neutropenia, Allo-HSCT (myeloma)              Fluconazole              0                                               7                   0.10                **400**
                                                                                                        3                                               7                   0.06                200
  7             57         F     Neutropenia/GVHD, Allo-HSCT (AML)             Fluconazole              0                                               7                   0.03                200
                                                                                                        7                                               7                   0.04                **300**
  8             75         F     Neutropenia, AML                              Fluconazole              0                                               41                  0.03                85
                                                                                                        3                                               7                   0.03                49
  9             36         M     Neutropenia, AML                              Posaconazole             0                                               7                   0.05                58
                                                                                                        3                                               7                   0.03                86
  10            52         F     Neutropenia, AML                              Posaconazole             0                                               7                   0.05                50
                                                                                                        11                                              7                   0.05                51

ALL, acute lymphoblastic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BDG, (1,3)-β-[d]{.smallcaps}-glucan; F, female; GM, galactomannan; GVHD, graft-versus-host disease; M, male; MS-DS, mass spectrometry method for detection of a serum disaccharide. Bold characters correspond to positive values.

**(ii) MS-DS diagnosis of IA in comparison to BDG and GM detection.** The distribution of BDG concentrations and MS-DS index values is shown in [Fig. 4](#F4){ref-type="fig"}. The values for the biomarkers were significantly higher in IA patients than in the controls (*P* ≤ 0.0001).

![Distribution of MS-DS indexes (A), GM indexes (B), and BDG concentrations (C) in patients with invasive aspergillosis (IA) and controls. The patient and control groups were compared using the Mann-Whitney test (significant at *P* ≤ 0.05). The dotted lines represent the cutoff values for each biomarker.](JCM.01867-18-f0004){#F4}

The sensitivity, specificity, and cutoff values for MS-DS and BDG detection were assessed by establishing ROC curves for serum, as shown in [Fig. 5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}. With a cutoff value of 325 for the MS-DS index, the sensitivity and specificity were 64% and 95%, respectively. The sensitivity values were intermediate between those for GM and BDG detection, which had 100% specificity. Interestingly, the 95% specificity of MS-DS was due to the high MS-DS index observed for control patient 6, who subsequently developed IA. In [Fig. 5C](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}, an analysis of MS-DS index values for IA diagnosis was performed for the patients, and no difference in terms of sensitivity and specificity was revealed with the data obtained for serum. A comparison of MS-DS and BDG detection ROC curves (according to the manufacturer's recommended threshold) showed that the diagnostic value of MS-DS was better than that of BDG detection, with a maximum sensitivity of 64% for MS-DS and 50% for BDG detection.

![(A, C) ROC curves for serum (A) and patients (C) for invasive aspergillosis (IA). (B, D) Sensitivity/specificity values according to preestablished cutoff values for each biomarker for analysis of serum (B) and patients (D). MS-DS\*, results obtained by exclusion of the control who developed IA 2 months later. Gray, dashed, and black lines, results for BDG detection, GM detection, and MS-DS, respectively.](JCM.01867-18-f0005){#F5}

[Figure 3B](#F3){ref-type="fig"} shows an example of MS-DS and BDG detection kinetic evolution during GM monitoring. For this patient, only one serum sample was positive at the GM cutoff 14 days after the beginning of monitoring, while BDG levels were already positive on day 0, before increasing at unusually high levels. MS-DS was constantly positive during the whole survey, although it decreased at the time when BDG levels and GM index values were maximum.

Mucormycosis. {#s3.3}
-------------

**(i) Study population.** The characteristics of patients and the level of certainty of a diagnosis of MM according to EORTC criteria are shown in [Table 5](#T5){ref-type="table"}. The genera/species involved were representative of the usual spectra of Mucorales isolated, as were the risk factors, infection sites, and high mortality.

###### 

Origin of the sera used in the MS-DS test for detection of mucormycosis[^*a*^](#T5F1){ref-type="table-fn"}

  Patient no. (site)   Age (yr)   Sex   Underlying condition(s)         Site(s) of MM                                    Imaging result                   Diagnostic sample   Histology/DE   Species                         MM level of certainty, EORTC   Treatment                                               Outcome   Delay vs time of mycological evidence (days)   *C~q~* value by PCR for Mucorales   BDG concn (pg/ml)   GM index in serum   MS-DS index
  -------------------- ---------- ----- ------------------------------- ------------------------------------------------ -------------------------------- ------------------- -------------- ------------------------------- ------------------------------ ------------------------------------------------------- --------- ---------------------------------------------- ----------------------------------- ------------------- ------------------- -------------
  1 (P)                27         M     Lymphoma                        Lung                                             Bronchiectasis, ground glass     Sputum              NA             *Syncephalastrum* sp. culture   Probable                       L-AMB                                                   Death     −15                                            Neg                                 NA                  \<0.5               3,333
                                                                                                                                                                                                                                                                                                                              0                                              Neg                                 NA                  \<0.5               123
                                                                                                                                                                                                                                                                                                                              7                                              Neg                                 NA                  \<0.5               278
  2 (P)                23         F     AML                             Lung                                             Nodule                           Biopsy              Hyphae         Lichtheimia corymbifera PCR     Proven                         L-AMB                                                   Death     −3                                             **40**                              NA                  \<0.5               37
  3 (P)                18         F     ALL                             Liver                                            Nodule                           Biopsy              Hyphae         *Mucor* sp. culture             Proven                         L-AMB                                                   Alive     45                                             Neg                                 NA                  \<0.5               **3,333**
                                                                                                                                                                                                                                                                                                                              51                                             Neg                                 NA                  \<0.5               **3,333**
  4 (P)                75         M     Myelodysplasia                  Rhinocerebral                                    Sinus, eye, and brain invasion   Conjunctival swab   Hyphae         *Lichtheimia* sp. culture       Proven                         No                                                      Death     −18                                            Neg                                 NA                  \<0.5               213
                                                                                                                                                                                                                                                                                                                              −14                                            **40**                              NA                  \<0.5               122
                                                                                                                                                                                                                                                                                                                              −7                                             **37**                              NA                  \<0.5               139
  5 (P)                72         M     AML                             Lung                                             Nodule                           Serum               NA             *Rhizomucor* sp. PCR            Possible                       L-AMB                                                   Death     0                                              **31**                              NA                  \<0.5               213
  6 (P)                77         F     ALL                             Lung                                             Nodule                           Serum               NA             *Mucor* sp. PCR                 Possible                       L-AMB                                                   Alive     30                                             **39**                              NA                  \<0.5               100
  7 (P)                19         F     Aplastic Fanconi anemia         Lung and kidney                                  Nodule                           Kidney biopsy       Hyphae         *Rhizomucor* sp. PCR            Proven                         L-AMB                                                   Death     45                                             **39**                              NA                  \<0.5               123
  8 (P)                57         M     AML                             Liver                                            Nodule                           Biopsy              Hyphae         *Lichtheimia* sp. culture       Proven                         L-AMB                                                   Death     −28                                            Neg                                 NA                  \<0.5               **333**
                                                                                                                                                                                                                                                                                                                              −21                                            Neg                                 NA                  \<0.5               66
                                                                                                                                                                                                                                                                                                                              −15                                            Neg                                 NA                  \<0.5               300
                                                                                                                                                                                                                                                                                                                              −7                                             Neg                                 NA                  \<0.5               149
                                                                                                                                                                                                                                                                                                                              0                                              **35**                              NA                  \<0.5               222
                                                                                                                                                                                                                                                                                                                              12                                             **31**                              NA                  \<0.5               **417**
                                                                                                                                                                                                                                                                                                                              19                                             **35**                              NA                  \<0.5               **1,000**
                                                                                                                                                                                                                                                                                                                              21                                             **39**                              NA                  \<0.5               **1,400**
                                                                                                                                                                                                                                                                                                                              30                                             Neg                                 NA                  \<0.5               **2,500**
                                                                                                                                                                                                                                                                                                                              34                                             Neg                                 NA                  \<0.5               **1,667**
                                                                                                                                                                                                                                                                                                                              41                                             Neg                                 NA                  \<0.5               **2,000**
                                                                                                                                                                                                                                                                                                                              53                                             Neg                                 NA                  \<0.5               **2,000**
                                                                                                                                                                                                                                                                                                                              63                                             Neg                                 NA                  \<0.5               **2,500**
  9 (L)                61         F     Allo-HSCT                       Lung                                             Nodule                           Biopsy              Hyphae         Rhizopus microsporus culture    Proven                         No                                                      Death     −4                                             **35**                              0                   0.07                132
  10 (L)               66         F     Burns, CML                      Skin                                             NA                               Swab                Neg            Lichtheimia ramosa culture      Possible                       NS                                                      Alive     −2                                             Neg                                 31                  NA                  132
                                                                                                                                                                                                                                                                                                                              5                                              **37**                              18                  NA                  159
  11 (L)               45         F     Allo-HSCT GVHD                  Postoperative abscess, abdominal wall (biopsy)   NA                               Biopsy              Hyphae         Rhizopus arrhizus culture       Proven                         Surgery, hyperbaric oxygen                              Death     −9                                             **33**                              42                  0.15                300
                                                                                                                                                                                                                                                                                                                              6                                              **34**                              46                  NA                  **2,000**
  12 (L)               42         M     Burns                           Skin                                             NA                               Biopsy              Hyphae         L. corymbifera culture          Proven                         L-AMB, surgery                                          Alive     24                                             Neg                                 21                  NA                  **1,429**
  13 (L)               83         F     Lymphoma, rituximab, diabetes   Lung                                             Nodule                           BAL fluid           Neg            R. microsporus culture          Probable                       No                                                      Death     −6                                             **35**                              18                  0.06                **455**
                                                                                                                                                                                                                                                                                                                              0                                              **35**                              0                   0.04                **400**
  14 (L)               76         M     Trauma                          Skin                                             NA                               Biopsy              Hyphae         Mucor circinelloides culture    Proven                         Switch from POSA to L-AMB, surgery, hyperbaric oxygen   Alive     16                                             Neg                                 39                  NA                  **3,333**
  15 (L)               60         M     Trauma                          Skin                                             NA                               Biopsy              Hyphae         M. circinelloides culture       Proven                         L-AMB, surgery                                          Alive     5                                              Neg                                 **106**             0.06                **3,333**
  16 (L)               3          F     ALL                             Disseminated                                     Disseminated                     Vitreous humor      Hyphae         *Lichtheimia* sp. PCR           Proven                         ISA/L-AMB                                               Alive     −1                                             Neg                                 18                  0.05                **333**

ALL, acute lymphoblastic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; BDG, (1,3)-β-[d]{.smallcaps}-glucan; CML, chronic myelogenous leukemia; *C~q~*, quantification cycle; DE, direct examination; EORTC, European Organization for Research and Treatment of Cancer; F, female; GM, galactomannan; GVHD, graft-versus-host disease; ISA, isavuconazole; L-AMB, liposomal amphotericin B; L, Lille, France; M, male; MM, mucormycosis; MS-DS, mass spectrometry method for detection of a serum disaccharide; NA, not available; Neg, negative; NS, not specified; P, Paris, France; POSA, posaconazole. Bold characters correspond to positive values.

**(ii) MS-DS in comparison with qPCR for diagnosis of MM.** In contrast to IC and IA, no biochemical or immunological assays for the detection of circulating fungal poly- or oligosaccharides are available for the diagnosis of MM. We therefore compared MS-DS with qPCR, which is the only test currently available for the diagnosis of MM. The qPCR method used detects species from the genera *Mucor*, *Rhizomucor*, *Lichtheimia*, and *Rhizopus*.

We tested 36 serum samples from 16 patients (1 to 13 serum samples/patient) by MS-DS and qPCR. The results for only 13 serum samples were concordant by both methods (positive or negative). Among the 23 serum samples with discordant results, 13 were positive by MS-DS only and 10 were positive by qPCR only. Only three patients were positive by both tests. Remarkably, all the patients in this series could be diagnosed with MM by at least one test.

The distribution of MS-DS index values in relation to the date of IFI diagnosis and in comparison to the qPCR results is shown in [Fig. 6](#F6){ref-type="fig"}. Among the serum samples tested before a mycological diagnosis was obtained, three (from three patients) were positive by MS-DS and six (from five patients) were positive by qPCR. An example of the kinetic evolution of MS-DS and qPCR in a patient from whom numerous samples were available is shown in [Fig. 3C](#F3){ref-type="fig"}. A steady increase in MS-DS index values was observed during the 2 months of follow-up, whereas DNA circulation could be detected only between day 0 and day 20.

![Distribution of DS in relation to the day of mycological diagnosis determined by MS-DS. Empty and full circles, negative and positive Mucorales qPCR results, respectively.](JCM.01867-18-f0006){#F6}

DISCUSSION {#s4}
==========

In contrast to diagnostic tests for obligate pathogens, whose detection is indicative of disease, diagnostic tests for opportunistic pathogens have to discriminate between the presence of microbes as endo- or exosaprophytes and their shift to a pathogen ([@B19]). This is a kinetic process where the assay has to present the best compromise between specificity and sensitivity over time from disease onset and its evolution to invasive infection. Currently, for IC and IA, only two types of tests have been shown to be clinically useful for disease management ([@B6], [@B21], [@B32], [@B33]). On the one hand, the Platelia Candida Ag Plus test and Platelia Aspergillus Ag test, which detect Man and GM, respectively, are considered specific but have a low sensitivity (especially for the detection of Man). On the other hand, the Fungitell test, which detects BDG, is considered more sensitive but less specific. The results of our previous study concerning MS-DS and those of the current study are in agreement with these conclusions. In both studies, MS-DS appeared to provide intermediate results, being more sensitive than the Platelia tests but more specific than the test for BDG ([@B28]). It is therefore suggested that MS-DS could be useful in the management of patients at risk of IC and IA.

For some other IFI, such as those caused by Mucorales, the lack of glucans in their cell wall and negativity for BDG in the context of host invasion have led to considerable efforts to develop alternative diagnostic methods; a specific PCR is now available ([@B24]). qPCR is of great help in the diagnosis of MM, whose emergence is worrying in terms of incidence and severity ([@B34]). MS-DS was previously shown to be positive during MM ([@B28]). In the present study, a comparison of the results of MS-DS with the results of qPCR showed a similar performance, confirming that a panfungal diagnostic assay is useful in daily practice when an IFI is suspected without mycological evidence. The reproducibility of the sensitivity values in mono- and multicenter studies confirms the robust character of the Platelia and BDG tests, in line with their extensive use worldwide for several decades. A similar reproducibility and, thus, robustness were observed for MS-DS. Additional information regarding MS-DS specificity concerned the absence of false positivity associated with *Nocardia* infection, in contrast to BDG detection, as reported previously ([@B35]) and as recently observed for one of the two patients included in this study. Conversely, among the three neutropenic patients who were included as IA controls and who were revealed to have subsequently developed IA, none were positive for either GM or BDG, while MS-DS index values were positive and above the limit of significance in two patients. Although these results could be considered a coincidence, the long delay before disease development should be considered with caution due to the possible subclinical character of DS circulation. Unpublished data described the structure and function of DS and showed that among the *m/z* 365 hex-disaccharide signals ([@B27]) is trehalose, an important fungal metabolite ([@B36]). What the present study, investigating four different IFI biomarkers in comparison with DS, makes particularly obvious is the different kinetics of their circulation, as shown in [Fig. 3](#F3){ref-type="fig"}. From a pathophysiological point of view, the metabolite DS has kinetics of synthesis and release from fungal cells different from those of cell surface-associated Man and GM or BDG, which is thought to be deeply anchored in the cell wall. These fungal polysaccharides are synthesized *in situ*, and then different processes of degradation take place as a result of either fungal or host carbohydrate catabolism. In parallel, binding to host receptors, catabolism by host soluble enzymes, and circulation as immune complexes make the levels in the circulation completely different. The efficiency of human mannosidases, naturally present for degrading human glycoproteins, and the large amount of antimannan antibodies present in IC patients are responsible for the rapid clearance of mannan. In contrast, mammals are poorly equipped for degrading glucans, which are not self-components, and their poor immunogenicity does not help with their clearance, explaining their longer persistence than mannans ([@B37], [@B38]). Despite considerable efforts to solve the problems of DNA extraction and standardization, the lack of knowledge regarding the relationship between clinical outcome and *Candida* PCR results has prevented clinical recommendations ([@B39]). Recent progress has been made by the association of PCR with magnetic resonance detection in the T2MR system, leading to good specificity and increased sensitivity with regard to blood cultures for IC ([@B25], [@B40]). For MM and in the absence of other biomarkers, qPCR represents significant progress, as demonstrated by a large collaborative study showing its ability to confirm the diagnosis. Furthermore, the survival rate was significantly higher in patients with an initially positive PCR result that became negative after treatment initiation than in patients whose PCR result remained positive ([@B41]). In our study, Mucorales qPCR and MS-DS were complementary since all serum samples were positive by at least one test. Although the significance of DS persistence should be compared to a positive PCR result, these results emphasize the benefit of MS-DS in patient care, principally due to the combination of biomarkers whose kinetics of synthesis and release differ during the pathogenic processes. The panfungal characteristics of MS-DS adapted to the broad diversity of emerging fungal pathogens presents some advantages for first-line screening. This simple, robust physicochemically based technology is easily implementable in the majority of clinical mycology laboratories now equipped with MALDI-TOF MS and can be adapted to single tests or a large series ([@B42]). However, as the present collaborative study was retrospective, its promising results have to be confirmed through a prospective study. More generally, this method, which allows the early identification and quantification of fungal glycans, is in its infancy, and studies are in progress to explore its potential. In parallel, studies concerning the contribution of MS-DS complemented with currently recommended tests are exploring the possibility of improving antifungal stewardship based on a better knowledge of the diagnostic and prognostic significance of glycobiomarkers.

\[This article was published on 26 April 2019 with Malgorzata Mikulska\'s surname incorrectly presented as \"Mikulska Malgorzata\" in the byline. The byline was updated in the current version, posted on 16 October 2019.\]
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